{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:35:15Z","timestamp":1790811315037,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.metabol.2023.155612","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T19:05:48Z","timestamp":1685819148000},"page":"155612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"145","author":[{"given":"Hye Jin","family":"Chun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai Hoon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong-Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2023.155612_bb0005","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2023.155612_bb0010","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155612_bb0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155612_bb0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4093\/dmj.2021.0327","article-title":"Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study","volume":"47","author":"Kim","year":"2023","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2023.155612_bb0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4093\/dmj.2020.0010","article-title":"Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the fatty liver research Group of the Korean Diabetes Association","volume":"44","author":"Lee","year":"2020","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2023.155612_bb0030","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4093\/dmj.2020.0115","article-title":"Nonalcoholic fatty liver disease: a drug revolution is coming","volume":"44","author":"Jeong","year":"2020","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2023.155612_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22063062","article-title":"Unexpected pleiotropic effects of SGLT2 inhibitors: pearls and pitfalls of this novel antidiabetic class","volume":"22","author":"Kaneto","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2023.155612_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4093\/dmj.2019.0208","article-title":"Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations","volume":"44","author":"Sheu","year":"2020","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2023.155612_bb0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4093\/dmj.2022.0209","article-title":"Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2023.155612_bb0050","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/15548627.2017.1356977","article-title":"Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition","volume":"13","author":"Kim","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.metabol.2023.155612_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01566","article-title":"Potential Nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: insulin resistance between hepatic and peripheral tissues","volume":"9","author":"Mu","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2023.155612_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/nu11091979","article-title":"Augmentation of glucotoxicity, oxidative stress, apoptosis and mitochondrial dysfunction in HepG2 cells by palmitic acid","volume":"11","author":"Alnahdi","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2023.155612_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fendo.2014.00221","article-title":"O-GlcNAc: a bittersweet switch in liver","volume":"5","author":"Zhang","year":"2014","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.metabol.2023.155612_bb0070","first-page":"1","article-title":"New insights into the biology of protein O-GlcNAcylation: approaches and observations","author":"Mueller","year":"2021","journal-title":"Frontiers Aging"},{"key":"10.1016\/j.metabol.2023.155612_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.761842","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors work as a \u201cregulator\u201d of autophagic activity in overnutrition diseases","volume":"12","author":"Fukushima","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2023.155612_bb0080","doi-asserted-by":"crossref","first-page":"58353","DOI":"10.18632\/oncotarget.16874","article-title":"Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice","volume":"8","author":"Obara","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.metabol.2023.155612_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children","volume":"20","author":"Kleiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.metabol.2023.155612_bb0090","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155612_bb0095","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155612_bb0100","doi-asserted-by":"crossref","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","article-title":"Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice","volume":"302","author":"Trevaskis","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.metabol.2023.155612_bb0105","doi-asserted-by":"crossref","first-page":"G378","DOI":"10.1152\/ajpgi.90543.2008","article-title":"Trans fat feeding results in higher serum alanine aminotransferase and increased insulin resistance compared with a standard murine high-fat diet","volume":"297","author":"Koppe","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.metabol.2023.155612_bb0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4093\/dmj.2021.0056","article-title":"DA-1241, a novel GPR119 agonist, improves Hyperglycaemia by inhibiting hepatic gluconeogenesis and enhancing insulin secretion in diabetic mice","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2023.155612_bb0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4093\/dmj.2019.0011","article-title":"Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis","volume":"43","author":"Lee","year":"2019","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2023.155612_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cotox.2019.03.001","article-title":"Human in vitro models of nonalcoholic fatty liver disease","volume":"16","author":"M\u00fcller","year":"2019","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.metabol.2023.155612_bb0125","first-page":"95","article-title":"Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells","volume":"2","author":"Cui","year":"2010","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.metabol.2023.155612_bb0130","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3892\/mmr.2020.11249","article-title":"Expression of Notch family is altered in non-alcoholic fatty liver disease","volume":"22","author":"Ding","year":"2020","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.metabol.2023.155612_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep09114","article-title":"Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers","volume":"5","author":"Kwan","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2023.155612_bb0140","first-page":"1","article-title":"The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2023.155612_bb0145","doi-asserted-by":"crossref","first-page":"16283","DOI":"10.1074\/jbc.M802240200","article-title":"O-GlcNAc regulates FoxO activation in response to glucose","volume":"283","author":"Housley","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2023.155612_bb0150","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI29044","article-title":"AMP-activated protein kinase signaling in metabolic regulation","volume":"116","author":"Long","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2023.155612_bb0155","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.3748\/wjg.v18.i46.6771","article-title":"Hepatic expression and cellular distribution of the glucose transporter family","volume":"18","author":"Karim","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2023.155612_bb0160","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00424-020-02417-x","article-title":"Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease","volume":"472","author":"Chadt","year":"2020","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.metabol.2023.155612_bb0165","doi-asserted-by":"crossref","first-page":"G1180","DOI":"10.1152\/ajpgi.00377.2013","article-title":"Dysregulated hepatic expression of glucose transporters in chronic disease: contribution of semicarbazide-sensitive amine oxidase to hepatic glucose uptake","volume":"307","author":"Karim","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.metabol.2023.155612_bb0170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1386-6346(01)00172-3","article-title":"Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model","volume":"23","author":"Okamoto","year":"2002","journal-title":"Hepatol Res"},{"key":"10.1016\/j.metabol.2023.155612_bb0175","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jhep.2006.10.021","article-title":"Identification of a gene-pathway associated with non-alcoholic steatohepatitis","volume":"46","author":"Rubio","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155612_bb0180","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3892\/ijmm.2015.2270","article-title":"Treatment with PPAR\u03b4 agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model","volume":"36","author":"Li","year":"2015","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.metabol.2023.155612_bb0185","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.metabol.2023.155612_bb0190","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.3390\/ijms20205237","article-title":"The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma","volume":"20","author":"Jojima","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2023.155612_bb0195","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME(R) trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2023.155612_bb0200","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF03180578","article-title":"Expression of mRNA for glucose transport proteins in jejunum, liver, kidney and skeletal muscle of pigs","volume":"65","author":"Aschenbach","year":"2009","journal-title":"J Physiol Biochem"},{"key":"10.1016\/j.metabol.2023.155612_bb0205","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cmet.2016.02.019","article-title":"Sodium intake regulates glucose homeostasis through the PPAR delta\/adiponectin-mediated SGLT2 pathway","volume":"23","author":"Zhao","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2023.155612_bb0210","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0304-4165(99)00176-2","article-title":"O-GlcNAc and the control of gene expression","volume":"1473","author":"Comer","year":"1999","journal-title":"BBA Gen Subjects"},{"key":"10.1016\/j.metabol.2023.155612_bb0215","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1194\/jlr.M004234","article-title":"Protein kinase Cbeta mediates hepatic induction of sterol-regulatory element binding protein-1c by insulin","volume":"51","author":"Yamamoto","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2023.155612_bb0220","doi-asserted-by":"crossref","first-page":"G825","DOI":"10.1152\/ajpgi.00145.2011","article-title":"Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition","volume":"301","author":"Charlton","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.metabol.2023.155612_bb0225","first-page":"8402035","article-title":"Identification of Sp1 as a transcription activator to regulate fibroblast growth factor 21 gene expression","volume":"2017","author":"Chen","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.metabol.2023.155612_bb0230","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1210\/en.2012-2009","article-title":"Clusterin decreases hepatic SREBP-1c expression and lipid accumulation","volume":"154","author":"Seo","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2023.155612_bb0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12192-020-01177-y","article-title":"O-GlcNAcylation: the \u201cstress and nutrition receptor\u201d in cell stress response","volume":"26","author":"Liu","year":"2021","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.metabol.2023.155612_bb0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbagen.2009.07.018","article-title":"O-linked beta-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress","volume":"1800","author":"Butkinaree","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2023.155612_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/nu13061740","article-title":"High fat activates O-GlcNAcylation and affects AMPK\/ACC pathway to regulate lipid metabolism","volume":"13","author":"Pang","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2023.155612_bb0250","first-page":"113","article-title":"Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy","author":"Otomo","year":"2020","journal-title":"Metab Clin Experiment"},{"key":"10.1016\/j.metabol.2023.155612_bb0255","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.3390\/cells11223637","article-title":"O-GlycNacylation remission retards the progression of non-alcoholic fatty liver disease","volume":"11","author":"Zhou","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.metabol.2023.155612_bb0260","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s10620-015-4025-x","article-title":"Function of autophagy in nonalcoholic fatty liver disease","volume":"61","author":"Czaja","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.metabol.2023.155612_bb0265","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1038\/s41467-018-05862-6","article-title":"mTOR-dependent phosphorylation controls TFEB nuclear export","volume":"9","author":"Napolitano","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2023.155612_bb0270","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1080\/15548627.2021.1898748","article-title":"AMPK-dependent phosphorylation is required for transcriptional activation of TFEB and TFE3","volume":"17","author":"Paquette","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.metabol.2023.155612_bb0275","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3389\/fendo.2018.00519","article-title":"AMP-activated protein kinase and O-GlcNAcylation, two partners tightly connected to regulate key cellular processes","volume":"9","author":"Gelinas","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2023.155612_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11658-020-00208-x","article-title":"Blockage of O-linked GlcNAcylation induces AMPK-dependent autophagy in bladder cancer cells","volume":"25","author":"Jin","year":"2020","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.metabol.2023.155612_bb0285","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J Hepatol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:33:24Z","timestamp":1758429204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049523002160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":57,"alternative-id":["S0026049523002160"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155612","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"155612"}}